|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM024534471 |
| 003 |
DE-627 |
| 005 |
20231221093622.0 |
| 007 |
tu |
| 008 |
231221s1989 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0082.xml
|
| 035 |
|
|
|a (DE-627)NLM024534471
|
| 035 |
|
|
|a (NLM)2472048
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Konami, T
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II) and adriamycin in urothelial cancer
|
| 264 |
|
1 |
|c 1989
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.07.1989
|
| 500 |
|
|
|a Date Revised 19.11.2015
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The VPM-CisA (vincristine (VCR), peplomycin (PLM), methotrexate (MTX), cisplatin (CDDP) and doxorubicin (ADM), regimen was used to treat 33 patients with urothelial tract tumors. Twenty-two patients had bi-dimensionally measurable disease parameters and 11 patients with locally advanced tumors were given postoperative adjuvant chemotherapy. The protocol consisted of 0.6 mg/m2 VCR on days 1 and 3, 3 mg/m2 PLM on days 1 to 4, 3 mg/m2 MTX on days 2 and 4, 35 mg/m2 CDDP on day 4, and 20 mg/m2 ADM on day 5. These doses were adjusted for each case: the above mentioned dose x [(80/(40+Age]2 +[(Karnofsky's performance status/100)2]. Of these patients, 28 (86 percent) were treated adequately, including 8 (36 per cent) who achieved a complete (2) or partial (6) remission. The mean duration of survival was 65.2 weeks for complete and partial responders, and 48.8 weeks for non-responders, which was not a statistically significant difference. Of 11, who were given post-operative adjuvant chemotherapy (mean observation period: 83.5 weeks) 9 were alive without evidence of disease, 1 had a recurrence 8 months after first chemotherapy, 1 died due to pulmonary and liver metastasis 2 years after the chemotherapy. Toxicity included mild myelosupression, moderate anorexia, vomiting, and severe gastric ulcer, pulmonary fibrosis
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Bleomycin
|2 NLM
|
| 650 |
|
7 |
|a 11056-06-7
|2 NLM
|
| 650 |
|
7 |
|a Peplomycin
|2 NLM
|
| 650 |
|
7 |
|a 56H9L80NIZ
|2 NLM
|
| 650 |
|
7 |
|a Vincristine
|2 NLM
|
| 650 |
|
7 |
|a 5J49Q6B70F
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Cisplatin
|2 NLM
|
| 650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
| 650 |
|
7 |
|a Methotrexate
|2 NLM
|
| 650 |
|
7 |
|a YL5FZ2Y5U1
|2 NLM
|
| 700 |
1 |
|
|a Wakabayashi, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ishida, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arai, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Konishi, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pak, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takeuchi, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tomoyoshi, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Watanabe, J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 35(1989), 2 vom: 16. Feb., Seite 231-7
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:1989
|g number:2
|g day:16
|g month:02
|g pages:231-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 1989
|e 2
|b 16
|c 02
|h 231-7
|